Overview

Genotypic Resistance Guided Versus Susceptibility Testing Guided Therapy for the First-line Eradication of H. Pylori

Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
We aimed to (1) compare the efficacy of genotypic resistance guided sequential therapy vs. susceptibility testing guided therapy in the first-line therapy (2) assess the long term impact of eradication therapy on the antibiotic resistance and microbiota of the gut flora and the metabolic factors in this multi-center, open labeled trial
Phase:
Phase 4
Details
Lead Sponsor:
National Taiwan University Hospital
Treatments:
Bismuth
Clarithromycin
Levofloxacin